Preclinical studies demonstrated its efficacy in inhibiting angiogenesis and tumor cell proliferation, particularly in FGFR1-amplified lung cancers and FGFR2-mutant endometrial cancers207,.216. This evidence concerns the gene FGFR1 and lung carcinoma.